» Articles » PMID: 26371427

Clinicopathologic Characteristics of Microsatellite Instable Gastric Carcinomas Revisited: Urgent Need for Standardization

Overview
Date 2015 Sep 16
PMID 26371427
Citations 68
Authors
Affiliations
Soon will be listed here.
Abstract

Microsatellite instable gastric cancer (MSI-GC) is a specific molecular subtype of GC. We studied the phenotypes, genotypes, and clinicopathologic characteristics of MSI-GC in a white GC cohort and compared our findings with an extended literature review. The study cohort consisted of 482 patients. Specimens were available from 452 cases and were used for immunostaining (MLH1, PMS2, MSH2, MSH6) and molecular biological analyses (BAT-25, BAT-26, NR-21, NR-24, NR-27; Epstein-Barr virus in situ hybridization). Thirty-four (7.5%) GCs were MSI. Loss of MLH1 and/or PMS2 was found in 30 (88%) MSI-GC, 3 (9%) showed loss of MSH2 and/or MSH6. One (3%) MSI-GC was identified only by molecular biological testing. A single case was heterogeneous and contained microsatellite-stable and instable tumor areas. Twenty-one (62%) MSI-GCs showed unusual histologic features. MSI-GC was not found in diffuse-type or Epstein-Barr virus-positive GC. MSI-GC was significantly more prevalent in elderly patients, distal stomach, and was associated with a significantly lower number of lymph node metastases and a significantly better overall and tumor-specific survival. MSI-GC constitutes a small but relevant subgroup of GC with distinct clinicopathologic characteristics. Our literature review illustrates the shortcomings of missing standardized testing algorithms with prevalences of MSI-GC ranging from 0% to 44.5%. Future studies should test the hypothesis that patients with MSI-GCs may not need adjuvant/perioperative chemotherapy. However, this will require a standardized, quality-controlled diagnostic algorithm of MSI for GC.

Citing Articles

Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP).

Alsina Maqueda M, Teijo Quintans A, Cuatrecasas M, Fernandez Acenero M, Fernandez Montes A, Gomez Martin C Clin Transl Oncol. 2025; .

PMID: 40072752 DOI: 10.1007/s12094-025-03865-6.


Harnessing Machine Learning and Nomogram Models to Aid in Predicting Progression-Free Survival for Gastric Cancer Patients Post-Gastrectomy with Deficient Mismatch Repair(dMMR).

Li Y, Ma J, Cheng W BMC Cancer. 2025; 25(1):141.

PMID: 39856598 PMC: 11759429. DOI: 10.1186/s12885-025-13542-0.


Spatial and Temporal Tumor Heterogeneity in Gastric Cancer: Discordance of Predictive Biomarkers.

Lee H J Gastric Cancer. 2025; 25(1):192-209.

PMID: 39822175 PMC: 11739643. DOI: 10.5230/jgc.2025.25.e3.


Digestive cancers: mechanisms, therapeutics and management.

Zhan T, Betge J, Schulte N, Dreikhausen L, Hirth M, Li M Signal Transduct Target Ther. 2025; 10(1):24.

PMID: 39809756 PMC: 11733248. DOI: 10.1038/s41392-024-02097-4.


Association of PD-L1 positivity with Epstein Barr virus infection and microsatellite instability in gastric carcinomas with lymphoid stroma.

Lee S, Oh H Sci Rep. 2024; 14(1):30932.

PMID: 39730741 PMC: 11680954. DOI: 10.1038/s41598-024-81764-6.


References
1.
Arai T, Sakurai U, Sawabe M, Honma N, Aida J, Ushio Y . Frequent microsatellite instability in papillary and solid-type, poorly differentiated adenocarcinomas of the stomach. Gastric Cancer. 2013; 16(4):505-12. DOI: 10.1007/s10120-012-0226-6. View

2.
Fang W, Chang S, Lan Y, Huang K, Lo S, Li A . Molecular and survival differences between familial and sporadic gastric cancers. Biomed Res Int. 2013; 2013:396272. PMC: 3603157. DOI: 10.1155/2013/396272. View

3.
Chiaravalli A, Cornaggia M, Furlan D, Capella C, Fiocca R, Tagliabue G . The role of histological investigation in prognostic evaluation of advanced gastric cancer. Analysis of histological structure and molecular changes compared with invasive pattern and stage. Virchows Arch. 2001; 439(2):158-69. DOI: 10.1007/s004280100441. View

4.
Warneke V, Behrens H, Haag J, Balschun K, Boger C, Becker T . Prognostic and putative predictive biomarkers of gastric cancer for personalized medicine. Diagn Mol Pathol. 2013; 22(3):127-37. DOI: 10.1097/PDM.0b013e318284188e. View

5.
Oki E, Kakeji Y, Zhao Y, Yoshida R, Ando K, Masuda T . Chemosensitivity and survival in gastric cancer patients with microsatellite instability. Ann Surg Oncol. 2009; 16(9):2510-5. DOI: 10.1245/s10434-009-0580-8. View